美国 · SEC FORM 4
NewAmsterdam Pharma Co N.V.
NAMS · Nasdaq · CIK 0001936258 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
1 qualifying P purchase group
当前 180 天评分窗口
19 同一窗口内观察到的 Form 4 交易行
9 sales · 9 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-09-14 · Davidson Michael H. · $226.5K
为什么没有活跃信号？
买入活动存在
近期买入1 qualifying line group(s)
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度与集中度
合资格买方1
买入集中度100%最大买方： Davidson Michael H. · $226.5K
聚集买入 · 15天1 insider峰值活动： 2026-09-14–2026-09-14
Roles in the peak window: Chief Executive Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Kooij Louise FrederikaChief Accounting Officer
○▼○▼○▼
Kastelein Johannes Jacob PieterChief Scientific Officer
○▼○▼
Davidson Michael H.Chief Executive Officer
●
Smither John WDirector
▼
Gunning Robert WilliamVice President, Controller
○
● 买入▼ 卖出○ 其他
—
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-09-14 · Davidson Michael H..
近期 Form 4 活动
1买入
43卖出
37其他 Form 4 交易行
28SEC 申报 · 365天
买入1 qualifying P line(s) · 180 days
卖出9 sale line(s) · 仅供背景
其他9 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 19,045,378
- 上期报告
- 15,660,444
- 日均成交量
- 2,028,041
- 回补天数
- 9.4
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Davidson Michael H. | 买入 (P) | Ordinary Shares | 10,000 | USD 22.65 | USD 226,500 | SEC 申报 ↗ |
| 2025-09-15 | Topper James N | 买入 (P) | Ordinary Shares | 660 | USD 23.70 | USD 15,642 | SEC 申报 ↗ |
| 2025-09-08 | Topper James N | 买入 (P) | Ordinary Shares | 1,260 | USD 24.99 | USD 31,487 | SEC 申报 ↗ |
| 2025-08-11 | Topper James N | 买入 (P) | Ordinary Shares | 471 | USD 23.98 | USD 11,295 | SEC 申报 ↗ |
| 2025-06-25 | Topper James N | 买入 (P) | Ordinary Shares | 1,260 | USD 18.26 | USD 23,008 | SEC 申报 ↗ |
| 2025-06-24 | Topper James N | 买入 (P) | Ordinary Shares | 2,520 | USD 18.43 | USD 46,444 | SEC 申报 ↗ |
| 2025-06-16 | Topper James N | 买入 (P) | Ordinary Shares | 8,584 | USD 19.50 | USD 167,388 | SEC 申报 ↗ |
| 2025-03-26 | Topper James N | 买入 (P) | Ordinary Shares | 1,135 | USD 22.49 | USD 25,526 | SEC 申报 ↗ |
| 2025-03-04 | Topper James N | 买入 (P) | Ordinary Shares | 4,005 | USD 21.02 | USD 84,185 | SEC 申报 ↗ |
| 2024-09-26 | Audet Juliette Berangere | 买入 (P) | Ordinary Shares | 1,104 | USD 15.70 | USD 17,333 | SEC 申报 ↗ |
| 2024-08-20 | Davidson Michael H. | 买入 (P) | Ordinary Shares | 5,000 | USD 16.27 | USD 81,350 | SEC 申报 ↗ |
| 2024-06-20 | Davidson Michael H. | 买入 (P) | Ordinary Shares | 5,000 | USD 17.26 | USD 86,300 | SEC 申报 ↗ |
| 2024-03-26 | Topper James N | 买入 (P) | Ordinary Shares | 8,429 | USD 21.50 | USD 181,224 | SEC 申报 ↗ |
| 2024-02-13 | LANGE LOUIS G | 买入 (P) | Ordinary Shares | 5,000 | USD 19.00 | USD 95,000 | SEC 申报 ↗ |
Form 4 申报证据
81 transaction lines in the latest 365-day window; 200 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Kastelein Johannes Jacob Pieter | 卖出 (S) | Ordinary Shares | 50,246 | USD 25.03 | USD 1,257,657 | SEC 申报 ↗ |
| 2026-09-30 | Kastelein Johannes Jacob Pieter | 期权行权／转换 (M) | Ordinary Shares | 50,246 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-14 | Davidson Michael H. | 买入 (P) | Ordinary Shares | 10,000 | USD 22.65 | USD 226,500 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Kastelein Johannes Jacob Pieter | 卖出 (S) | Ordinary Shares | 50,246 | USD 25.03 | USD 1,257,657 | SEC 申报 ↗ |
| 2026-09-30 | Kastelein Johannes Jacob Pieter | 期权行权／转换 (M) | Ordinary Shares | 50,246 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-14 | Davidson Michael H. | 买入 (P) | Ordinary Shares | 10,000 | USD 22.65 | USD 226,500 | SEC 申报 ↗ |
| 2026-09-04 | Smither John W | 卖出 (S) | Ordinary Shares | 1,600 | USD 25.32 | USD 40,512 | SEC 申报 ↗ |
| 2026-09-01 | Gunning Robert William | 奖励／授予 (A) | Ordinary Shares | 3,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-24 | Kastelein Johannes Jacob Pieter | 卖出 (S) | Ordinary Shares | 125,000 | USD 26.91 | USD 3,363,750 | SEC 申报 ↗ |
| 2026-08-24 | Kastelein Johannes Jacob Pieter | 期权行权／转换 (M) | Ordinary Shares | 125,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-20 | Kooij Louise Frederika | 卖出 (S) | Ordinary Shares | 105,000 | USD 30.34 | USD 3,185,656 | SEC 申报 ↗ |
| 2026-07-20 | Kooij Louise Frederika | 期权行权／转换 (M) | Ordinary Shares | 105,000 | USD 11.34 | USD 1,191,100 | SEC 申报 ↗ |
| 2026-06-22 | Kooij Louise Frederika | 卖出 (S) | Ordinary Shares | 40,000 | USD 30.20 | USD 1,208,159 | SEC 申报 ↗ |
| 2026-06-22 | Kooij Louise Frederika | 期权行权／转换 (M) | Ordinary Shares | 40,000 | USD 11.28 | USD 451,000 | SEC 申报 ↗ |
| 2026-05-26 | Kooij Louise Frederika | 卖出 (S) | Ordinary Shares | 65,000 | USD 35.69 | USD 2,319,850 | SEC 申报 ↗ |
| 2026-05-26 | Kooij Louise Frederika | 期权行权／转换 (M) | Ordinary Shares | 65,000 | USD 10.07 | USD 654,500 | SEC 申报 ↗ |
| 2026-03-11 | LANGE LOUIS G | 卖出 (S) | Ordinary Shares | 44,619 | USD 30.42 | USD 1,357,230 | SEC 申报 ↗ |
| 2026-03-09 | LANGE LOUIS G | X (X) | Ordinary Shares | 44,619 | USD 11.50 | USD 513,118 | SEC 申报 ↗ |
| 2026-03-09 | Kastelein Johannes Jacob Pieter | 卖出 (S) | Ordinary Shares | 101,409 | USD 30.29 | USD 3,071,679 | SEC 申报 ↗ |
| 2026-03-09 | Kastelein Johannes Jacob Pieter | 期权行权／转换 (M) | Ordinary Shares | 101,409 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-06 | LANGE LOUIS G | 卖出 (S) | Ordinary Shares | 28,186 | USD 29.41 | USD 828,950 | SEC 申报 ↗ |
| 2026-03-06 | Kastelein Johannes Jacob Pieter | 卖出 (S) | Ordinary Shares | 94,124 | USD 30.32 | USD 2,853,840 | SEC 申报 ↗ |
| 2026-03-06 | Kastelein Johannes Jacob Pieter | 期权行权／转换 (M) | Ordinary Shares | 94,124 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-05 | Kastelein Johannes Jacob Pieter | 卖出 (S) | Ordinary Shares | 104,467 | USD 30.30 | USD 3,165,350 | SEC 申报 ↗ |
| 2026-03-05 | Kastelein Johannes Jacob Pieter | 期权行权／转换 (M) | Ordinary Shares | 104,467 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-02 | Davidson Michael H. | 卖出 (S) | Ordinary Shares | 443,707 | USD 33.25 | USD 14,753,258 | SEC 申报 ↗ |
| 2026-03-02 | Davidson Michael H. | 期权行权／转换 (M) | Ordinary Shares | 443,707 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-26 | Davidson Michael H. | 卖出 (S) | Ordinary Shares | 183,332 | USD 33.71 | USD 6,179,974 | SEC 申报 ↗ |
| 2026-02-26 | Davidson Michael H. | 期权行权／转换 (M) | Ordinary Shares | 183,332 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-25 | Davidson Michael H. | 卖出 (S) | Ordinary Shares | 58,253 | USD 35.30 | USD 2,056,174 | SEC 申报 ↗ |
| 2026-02-25 | Davidson Michael H. | 期权行权／转换 (M) | Ordinary Shares | 58,253 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-24 | Davidson Michael H. | 卖出 (S) | Ordinary Shares | 64,708 | USD 36.15 | USD 2,338,943 | SEC 申报 ↗ |
| 2026-02-24 | Davidson Michael H. | 期权行权／转换 (M) | Ordinary Shares | 64,708 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | NAMS |
| CIK | 0001936258 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 200 transaction lines from 2024-02-13 to 2026-09-30 14 P purchase lines · 102 S sale lines · 84 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.